Induction therapy for pediatric and adult heart transplantation: Comparison between OKT3 and daclizumab

Transplantation

Volumn 80, Issue 4, 2005, Pages 477-481

  Chin, Clifford ^a,b   Pittson, Sky ^a   Luikart, Helen ^a   Bernstein, Daniel ^a   Robbins, Robert ^a   Reitz, Bruce ^a   Oyer, Phillip ^a   Valantine, Hannah ^a  

^a STANFORD UNIVERSITY   (United States)

^b Division of Pediatric Cardiology   (United States)

Author keywords

Daclizumab; Induction; OKT3; Pediatric

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; DIPHENHYDRAMINE; HYDROCORTISONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SAFETY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOPSY; CHILD; ENDOCARDIUM; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MIDDLE AGED; MUROMONAB-CD3; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 23944465377     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000168153.50774.30     Document Type: Article

References (22)

1. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study. J Heart Lung Transplant 1993; 12: 549.
2. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: A multicenter study. J Heart Lung Transplant 1999; 18: 460.
3. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613.
4. Lietz K, Ranjit J, Beniaminovitz A, et al. Interleukin-2 receptor blockade in cardiac transplantation: Influence of HLA-DR locus incompatibility on treatment efficacy. Transplantation 2003; 75: 781.
5. Sarris GE, Moore KA, Schroeder JS, et al. Cardiac transplantation: The Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 1994; 108: 240.
6. Starnes VA, Oyer PE, Stinson EB, et al. Prophylactic OKT3 used as induction therapy for heart transplantation. Circ 1989; 80: III79.
7. Kirklin JK, Bourge RC, White-Williams C, et al. Prophylactic therapy for rejection after cardiac transplantation: A comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg 1990; 99: 716.
8. Robbins RC, Barlow CW, Oyer PE, et al. Thirty years of cardiac transplantation at Stanford University. J Heart Lung Transplant 1999; 117: 939.
9. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
10. Stock PG, Lantz M, Light S, Vincenti F. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc 1996; 28: 915.
11. Balk AH, Simoons ML, Jutte NH, et al. Sequential OKT3 and cyclosporine after heart transplantation: A randomized study with single and cyclic OKT3. Clin Transplant 1991; 5: 301.
12. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: A prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001; 20: 1282.
13. Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: A comparison of two different rabbit-antithymocyte globulines. Transplantation 2000; 69: 1890.
14. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
15. Chin C, Naftel DC, Singh TP, et al. Risk factors for recurrent rejection in pediatric heart transplantation: A multicenter experience. J Heart Lung Transplant 2000; 19: 71.
16. Ventura H, Kirklin J, Eisen H, et al. The combined impact of pretransplant risk factors and rejection frequency and severity on the prevalence of post-transplant coronary vasculopathy. J Heart Lung Transplant 1997; 16: 66.
17. Mills RM, Naftel DC, Kirklin JK, et al. Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate. J Heart Lung Transplant 1997; 16: 813.
18. Pahl E, Naftel DC, Canter CE, et al. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: A multi-institutional study. J Heart Lung Transplant 2001; 20: 279.
19. Jeyarah DR, Thistlethwaite JR. General aspects of Cytokine-Release Syndrome: Timing and incidence of symptoms. Transplant Proc 1993; 25: 16.
20. Thistlethwaite JR, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112.
21. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320.
22. Product Information. Zenapax dRL, Nutley, NJ. PI revised 07/2003, reviewed 08/2003.